tetano
Editor, Senior Moderator
Angew Chem Int Ed Engl. 2012 Nov 13. doi: 10.1002/anie.201204062. [Epub ahead of print]
Chemical Probes for Drug-Resistance Assessment by Binding Competition (RABC): Oseltamivir Susceptibility Evaluation.
Cheng TJ, Wang SY, Wen WH, Su CY, Lin M, Huang WI, Liu MT, Wu HS, Wang NS, Cheng CK, Chen CL, Ren CT, Wu CY, Fang JM, Cheng YS, Wong CH.
Source
The Genomics Research Center, Academia Sinica, Taipei, 11529 (Taiwan).
Abstract
The wizard of OS (resistance): The binding difference of neuraminidase inhibitors (zanamivir versus oseltamivir (OS)) was used to establish an assay to identify the influenza subtypes that are resistant to OS but still sensitive to zanamivir. This assay used a zanamivir-biotin conjugate to determine the OS susceptibility of a wide range of influenza viruses and over 200 clinical isolates.
Copyright ? 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PMID:
23150231
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23150231
Chemical Probes for Drug-Resistance Assessment by Binding Competition (RABC): Oseltamivir Susceptibility Evaluation.
Cheng TJ, Wang SY, Wen WH, Su CY, Lin M, Huang WI, Liu MT, Wu HS, Wang NS, Cheng CK, Chen CL, Ren CT, Wu CY, Fang JM, Cheng YS, Wong CH.
Source
The Genomics Research Center, Academia Sinica, Taipei, 11529 (Taiwan).
Abstract
The wizard of OS (resistance): The binding difference of neuraminidase inhibitors (zanamivir versus oseltamivir (OS)) was used to establish an assay to identify the influenza subtypes that are resistant to OS but still sensitive to zanamivir. This assay used a zanamivir-biotin conjugate to determine the OS susceptibility of a wide range of influenza viruses and over 200 clinical isolates.
Copyright ? 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PMID:
23150231
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23150231